Skip to content

    Recently Viewed

      Listening...

      Home / Our Company / Our societal impact / Global Health Equity /
      Advancing equitable access to care

      Advancing equitable access to care

      Everyone should have the opportunity to lead a healthy life. This requires that we advance equitable access to healthcare and address some of the world’s most devastating and neglected diseases.

      That’s why Johnson & Johnson has long taken action to advance equitable access to our lifesaving medicines and health technologies and focuses on addressing diseases that disproportionately impact people in lower- and middle-income countries. These efforts resulted in our rise to second place in the 2022 Access to Medicine Index (ATMI), marking the sixth consecutive time Johnson & Johnson has featured among the top three performers in the Index and validating our decades-long, deliberate and focused access strategy.
      Expand
      Our colleagues and partners around the world work together every day to enable access to our innovative medicines and technologies in almost 100 lower- and middle-income countries. We apply access & pricing principles across our entire pharmaceutical portfolio, planning for access early in the research phase, while our dedicated global public health team applies a lab-to-last-mile approach to fight diseases like tuberculosis, HIV, Ebola, and intestinal worms: innovating across all that we do to develop and deliver much-needed medicines, strengthening health systems and supporting frontline health workers.

      We recognize much more needs to be done and will continue working tirelessly, building on our approach to meet the needs of people today and the challenges the world faces tomorrow.
      Collapse
      hqdefault.jpg

      More than a decade of access leadership

      The impact of our efforts to advance access to medicines is reflected in Johnson & Johnson’s consistent high rank in the ATMI, which evaluates global companies’ access to medicine efforts. In 2022, we rose to second place, from third in 2021, marking the sixth consecutive time we’ve ranked among the top three companies worldwide, and underscoring the enduring nature of our commitment to people impacted by devastating and neglected diseases.
      6 red squares containing white numbers

      Our commitment to advance access to medicines and technologies

      Latest news
      A young child taking medication

      Improving access to medicine around the world

      Johnson & Johnson earned the #2 spot on the Access to Medicine Index, an important measurement of the company’s longstanding commitment to make lifesaving medicine available and accessible to those who need it most.

      Champions of access

      • Through our access and pricing principles we are able to systematically plan for access across our entire portfolio, beginning at the early stages of discovery and development, ensuring that our medicines reach the people who need them most.
        Jennifer Taubert
        Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson
      • From addressing endemic diseases like tuberculosis to emerging health threats like Ebola and dengue, we design innovative medicines and technologies that are fit for purpose for every community.
        Rusandra Draghia-Akli, M.D., Ph.D.
        Global Head, Global Public Health R&D
      • Our consistent track record validates our long-standing, focused strategy and is a testament to the work of our colleagues and partners around the world who work every day to meet the needs of patients in almost 100 LMICs.
        Vanessa Broadhurst
        Executive Vice President, Global Corporate Affairs
      1 of 3
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.